ADMA Biologics, Inc. (NASDAQ:ADMA – Get Rating) has earned an average recommendation of “Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $5.70.
ADMA has been the topic of several recent research reports. StockNews.com assumed coverage on ADMA Biologics in a report on Thursday, March 31st. They set a “sell” rating on the stock. Zacks Investment Research raised ADMA Biologics from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Morgan Stanley lifted its stake in ADMA Biologics by 10.5% in the second quarter. Morgan Stanley now owns 420,606 shares of the biotechnology company’s stock valued at $674,000 after purchasing an additional 40,030 shares during the last quarter. Raymond James & Associates lifted its stake in ADMA Biologics by 23.6% in the third quarter. Raymond James & Associates now owns 152,183 shares of the biotechnology company’s stock valued at $172,000 after purchasing an additional 29,029 shares during the last quarter. BlackRock Inc. lifted its stake in ADMA Biologics by 7.9% in the third quarter. BlackRock Inc. now owns 2,351,367 shares of the biotechnology company’s stock valued at $2,657,000 after purchasing an additional 173,135 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in ADMA Biologics by 66.9% in the third quarter. Goldman Sachs Group Inc. now owns 238,345 shares of the biotechnology company’s stock valued at $270,000 after purchasing an additional 95,540 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in ADMA Biologics by 24.7% in the third quarter. Geode Capital Management LLC now owns 1,313,094 shares of the biotechnology company’s stock valued at $1,483,000 after purchasing an additional 259,767 shares during the last quarter. Hedge funds and other institutional investors own 55.15% of the company’s stock.
ADMA Biologics (NASDAQ:ADMA – Get Rating) last issued its earnings results on Wednesday, May 11th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). ADMA Biologics had a negative net margin of 83.27% and a negative return on equity of 59.36%. During the same period last year, the company posted ($0.16) earnings per share. Research analysts predict that ADMA Biologics will post -0.31 EPS for the current fiscal year.
About ADMA Biologics (Get Rating)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
- Get a free copy of the StockNews.com research report on ADMA Biologics (ADMA)
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.